Aim: Healthcare resources usage and costs associated to nonvalvular atrial fibrillation
(NVAF) were analyzed in Spain. Methods: This is an observational and retrospective study …

Introduction and objectives Cost-effectiveness analysis of apixaban (5 mg twice daily) vs
acenocoumarol (5 mg/day) in the prevention of stroke in patients with nonvalvular atrial …

Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …

Objective Nonvalvular atrial fibrillation (NVAF) is a risk factor for ischemic stroke and
systemic embolism. New oral anticoagulants are currently available. The objective of this …

Purpose: To estimate the effectiveness of apixaban relative to warfarin in NVAF
anticoagulation suitable population in Argentina. Methods: A literature review was …

Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …

Background: Patients with non-valvular atrial fibrillation (NVAF) have an increased risk of
stroke and are often treated with oral anticoagulants (ie warfarin). However, apixaban, a …

Objectives To assess the cost-effectiveness of apixaban versus rivaroxaban in the
prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in Spain. Methods …

Objectives To evaluate the cost-effectiveness of apixaban in the prevention of stroke in
patients with non-valvular atrial fibrillation (NVAF) from a French payer perspective. Methods …

BACKGROUND Atrial fibrillation (AF) is associated with development of thromboembolic
events [1]. The standard therapy used in patients with non-valvular atrial fibrillation (NVAF) …